Key points for investors:
- Strong full-year 2025 results: Group revenue CHF 2.6 billion (organic growth 8.9%); reported growth 4.1% (translation headwind ~CHF 100m). Core gross margin 70.1%; core EBIT margin 26.5% at constant 2024 rates (25.2% including FX). Core net result CHF 478m; free cash flow CHF 290m (11.1% of revenue).
- Product & digital momentum: Record new-product launches. iEXCEL implant: >1 million sold since launch (company’s fastest-adopted implant). SIRIOS X3 scanner launched Oct 2025 with strong early demand. Straumann AXS platform reached >15,000 active users in ~18 months.
- Orthodontics transformation: ClearCorrect manufacturing transition to Smartee (EMEA & APAC) progressing; expected margin and COGS benefits to materialize through H2 2026 and beyond. New product features (scalloped trimline, mandibular repositioning) planned to broaden addressable cases.
- China & regulatory risk: Second-half 2025 softness driven by weaker patient flow and distributor destocking ahead of Value-Based Procurement (VBP). Management assumes VBP timing around Q2 2026; expects a stronger H2 2026 as VBP ramps and local Shanghai manufacturing scales.
- Capital allocation & sustainability: CapEx in 2025 CHF 223m (one of the highest years) focused on Shanghai ramp, Curitiba site, and innovation. Board proposes dividend CHF 1.00/share (+5%). Progress on sustainability (Scope 1/2 emissions down ~17% vs 2021; 98.5% renewable electricity).
- 2026 outlook and execution priorities: Management expects high single-digit organic revenue growth in 2026 and core EBIT margin expansion of 30–60 bps at constant 2025 FX. Growth playbook: (1) perform in core implants & regenerative via innovation/digital/education, (2) transform orthodontics for scale and profitability, (3) disrupt chairside prosthetics via scanners, printers, materials and the AXS ecosystem.
- Risks and near-term headwinds: FX volatility and U.S. tariffs (c. CHF 20m COGS hit in 2025, expected similar in 2026), timing/impact of China VBP and distributor destocking, transitional costs for ClearCorrect, and continued macro/regulatory uncertainty.
Overall take: Straumann delivered resilient growth, margin resilience and strong cash conversion in 2025 despite FX/tariff headwinds; major strategic transitions (orthodontics manufacturing, digital ecosystem and China localization) are underway and expected to drive stronger profitability and share gains in 2026+, but investors should monitor China VBP timing, FX/tariff exposure and the pace of ClearCorrect ramp to Smartee.
Sign In
Buy SAUHY
